Compare New York Times Co (NYT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Sana Biotechnology Inc — how do they compare? New York Times Co trades at $66.8 (market cap $10.96B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: New York Times Co is far larger — about 10.6× Sana Biotechnology Inc's market cap, and New York Times Co pays a 1.35% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NYT | SANA | |
|---|---|---|
Market Cap | $10.96B | $1.03B |
Sector | Media | Health |
52-Week High | $85.86 | $5.92 |
52-Week Low | $54.66 | $2.68 |
Enterprise Value | $10.36B | $946.04M |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $67.96, up 1.01% today, with a neutral technical signal and mixed moving averages. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.69 exceeding the $0.663 forecast. Revenue growth is steady, rising from $2.3B in 2022 to $2.8B in 2025, with net profit margins improving to 12.17%. The company maintains strong cash flow from operations at $584.49M in 2025. Analyst consensus is a $76.00 price target, though the majority recommend Hold.
Outlook remains cautiously optimistic given earnings momentum and solid fundamentals, but risks include the ongoing OpenAI copyright lawsuit and competitive pressures in digital media. The stock offers potential upside to the consensus target, supported by institutional buying interest, though sentiment is tempered by regulatory and litigation uncertainties.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
